Your browser doesn't support javascript.
loading
Relapse in ocular tuberculosis: relapse rate, risk factors and clinical management in a non-endemic country.
Putera, Ikhwanuliman; Ten Berge, Josianne C E M; Thiadens, Alberta A H J; Dik, Willem A; Agrawal, Rupesh; van Hagen, P Martin; La Distia Nora, Rina; Rombach, Saskia M.
Afiliação
  • Putera I; Department of Ophthalmology, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia i.putera@erasmusmc.nl s.rombach@erasmusmc.nl.
  • Ten Berge JCEM; Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • Thiadens AAHJ; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • Dik WA; Department of Internal Medicine Section Allergy and Clinical Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • Agrawal R; Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • van Hagen PM; Department of Ophthalmology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • La Distia Nora R; Laboratory Medical Immunology, Department of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  • Rombach SM; National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore.
Br J Ophthalmol ; 2024 Apr 12.
Article em En | MEDLINE | ID: mdl-38609164
ABSTRACT

AIMS:

To assess the risk of uveitis relapse in ocular tuberculosis (OTB) following clinical inactivity, to analyse clinical factors associated with relapses and to describe the management strategies for relapses.

METHODS:

A retrospective study was conducted on a 10-year patient registry of patients with OTB diagnosed at Erasmus MC in Rotterdam, The Netherlands. Time-to-relapse of uveitis was evaluated with Kaplan-Meier curve and risk factors for relapses were analysed.

RESULTS:

93 OTB cases were identified, of which 75 patients achieved clinical inactivity following treatment. The median time to achieve uveitis inactivity was 3.97 months. During a median follow-up of 20.7 months (Q1-Q3 5.2-81.2) after clinical inactivity, uveitis relapse occurred in 25 of these 75 patients (33.3%). Patients who were considered poor treatment responders for their initial uveitis episode had a significantly higher risk of relapse after achieving clinical inactivity than good responders (adjusted HR=3.84, 95% CI 1.28 to 11.51). 13 of the 25 relapsed patients experienced multiple uveitis relapse episodes, accounting for 78 eye-relapse episodes during the entire observation period. Over half (46 out of 78, 59.0%) of these episodes were anterior uveitis. A significant number of uveitis relapse episodes (31 episodes, 39.7%) were effectively managed with topical corticosteroids.

CONCLUSIONS:

Our results suggest that approximately one-third of patients with OTB will experience relapse after achieving clinical inactivity. The initial disease course and poor response to treatment predict the likelihood of relapse in the long-term follow-up. Topical corticosteroids were particularly effective in relapse presenting as anterior uveitis.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article